Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Effect (Details) - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Total shares of common stock equivalents (in shares) | 13,856,446 | 8,337,419 |
| Options to purchase common stock | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Total shares of common stock equivalents (in shares) | 11,008,350 | 8,337,419 |
| Purchase warrants | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Total shares of common stock equivalents (in shares) | 2,848,096 | 0 |